Navigation Links
OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
Date:5/15/2012

PARIS, May 15, 2012 /PRNewswire/ -- OrbusNeich today announced that 12-month follow-up data from the REMEDEE study showed favorable clinical and safety outcomes involving the use of the company's Combo Dual Therapy Stent when compared to the TAXUS® Liberte® paclitaxel-eluting stent. The data were presented by Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, at EuroPCR 2012.

In the 12-month follow-up data set, the clinically driven target lesion failure (TLF) rate was 8.9% for patients treated with the Combo Stent, compared to 10.2% for those treated with the TAXUS stent. Clinically driven TLF was defined as a composite of death, myocardial infarction (MI) and clinically driven target lesion revascularization (TLR). In addition, the rate of clinically driven TLR was 4.9% for patients treated with the Combo Stent, compared to 8.5% for those treated with the TAXUS stent. There was no stent thrombosis (ST) in either of the groups.

"The in-stent and in-segment late loss and binary restenosis rates were accordingly low for the Combo Stent and comparable to those of the TAXUS stent," said Prof. Haude. "Additionally, we saw a uniform, homogeneous neointimal response with the Combo Stent, compared to the more heterogeneous and layered neointimal tissue appearance with the TAXUS stent. Other data are being presented this week, and we look forward to presenting two-year follow-up and other results of the REMEDEE study at upcoming conferences."

REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) is a randomized clinical trial designed to demonstrate the safety and efficacy of the Combo Dual Therapy Stent compared to the TAXUS stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. The study's primary en
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. Combo method reveals cells signal systems
3. Computer-designed molecules point to new therapy for cystic fibrosis
4. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
5. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
6. Cell Therapy - Technologies, Markets and Companies
7. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
8. Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
9. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014 Cloud ... drug design and development, announced today the expansion ... company has been granted supercomputing time at Argonne ... targets.  Through a discretionary allocation ... Computing Facility (ALCF), researchers at Cloud Pharmaceuticals will ...
(Date:7/14/2014)... Canada (PRWEB) July 14, 2014 ... executives from across the clinical trials space, representing ... eCongress webinar series entitled “Optimizing Patient Participation in ... eCongress kicked off with internationally renowned R&D expert, ... Keynote address on Reinventing Drug Development through Patient ...
(Date:7/14/2014)... -- Minerva Neurosciences (NASDAQ: NERV ), a ... neuropsychiatric diseases and disorders, today announced that Frederick ... finance and chief accounting officer, effective June 2, 2014.  ... more than 20 years of experience in directing the ... background includes the management of compliance and reporting requirements ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... registry platform, announced that three PatientCrossroads-based patient ... the Phelan-McDermid Syndrome International Registry; and the ... been awarded contracts by the Patient-Centered Outcomes ... creation of a new health data network ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... , BEIJING, Sept. 16 ... hospital groups, has announced it will broaden inclusion,criteria ... study will use,stem cells derived from peripheral blood ... of diabetic foot ulcers involves intensive,wound management, risk ...
... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... from the U.S. Food and Drug Administration (FDA) for ...
... , , , SAN ... it is relaunching its oligonucleotide radiolabeling services. TriLink discontinued the ... that the market may no longer require it. However, strong ... in September 2009. , , "We,ve learned ...
Cached Biology Technology:Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 2Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 3Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 4AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services 2
(Date:7/14/2014)... How does oxygen control insect body size? What influence does ... first issue of Current Opinion in Insect Science ... questions. , Current Opinion in Insect Science is ... is a review journal that aims to provide specialists with ... of information published in the field of insect science. First ...
(Date:7/14/2014)... Foundation (BGRF), a UK-based charity founded to support ... rapidly ageing population, hosted the inaugural 21st Century ... Analytics, a company supporting financial decision-making in the ... at the forum included: , Dmitry Kamenskiy, Senior ... Investment to Advance Longevity Research, , Kate Elizarova, ...
(Date:7/14/2014)... University of Kansas scientists to the discovery and description of ... in collections specimen, which turned out to represent a new ... enigmatic ripidiine wedge beetle from Borneo is discussed in a ... ZooKeys . , The holotype male, and only known ... ago in Borneo but subsequent to this it was transferred ...
Breaking Biology News(10 mins):BGRF hosts inaugural 21st Century Medicine Forum 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3
... space activities, a silent revolution is taking place at ... first human-rated spacecraft to be launched from Europe,s Spaceport, ... pressurised module of the largest, most complex automated spacecraft ... fulfilling the most stringent rules of human spaceflight. , ...
... to pass genes to the next generation. In sexually ... that are vital for fertility. In a new study ... researchers at Cornell University knocked down the levels of ... the males abilities to modulate egg production, sperm storage ...
... Washington University School of Medicine in St. Louis have ... plague women with urinary tract infections (UTIs) are entrenched ... controversial revision of scientists, model of how bacteria cause ... for infections get into the bladder but do not ...
Cached Biology News:Final preparations for first human-rated spacecraft to be lauched from Europe's Spaceport 2Final preparations for first human-rated spacecraft to be lauched from Europe's Spaceport 3Bacteria that cause urinary tract infections invade bladder cells 2Bacteria that cause urinary tract infections invade bladder cells 3
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
... versatile Promega Flipper® Racks are ideal for ... small tubes. These polypropylene racks withstand extreme ... freezer storage. They may also be autoclaved ... is two-sided; one side accommodates 0.5ml microcentrifuge ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Biology Products: